MDLZ
22
-16
DVA
52
-2
DG
74
-2
BA
42
4
TAP
38
-2
NVDA
47
-5
RL
82
2
VLO
50
-5
MAT
45
-7
GD
57
-6
PNW
60
-4
CA
21
-6
SEE
56
3
MAS
60
-2
CL
59
3
HOG
35
-3
C
79
-2
WYNN
34
-3
FITB
76
-4
CCL
65
-3
MDLZ
22
-16
DVA
52
-2
DG
74
-2
BA
42
4
TAP
38
-2
NVDA
47
-5
RL
82
2
VLO
50
-5
MAT
45
-7
GD
57
-6
PNW
60
-4
CA
21
-6
SEE
56
3
MAS
60
-2
CL
59
3
HOG
35
-3
C
79
-2
WYNN
34
-3
FITB
76
-4
CCL
65
-3
Financhill
Back

Sarepta Therapeutics, Inc. Stock Predictions

14K Investors Got In Earlier. You Still Can.

DISCLOSURE: This is a paid advertisement for RAD Intel's Reg A offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks at invest.radi
Sell
50

SRPT
Sarepta Therapeutics, Inc.

Last Price:
$21.55
Seasonality Move:
10.87%

7 Day Trial

ALL ACCESS PASS

$ 7

Share Price Moved. Momentum Hasn't Slowed.

DISCLOSURE: This is a paid advertisement for RAD Intel's Reg A offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks at invest.radi

Sarepta Therapeutics, Inc. Stock Forecast

  • Over the next 52 weeks, Sarepta Therapeutics, Inc. has on average historically risen by 28.1% based on the past 28 years of stock performance.
  • Sarepta Therapeutics, Inc. has risen higher in 13 of those 28 years over the subsequent 52-week period, corresponding to a historical accuracy of 46.43%
  • Is Sarepta Therapeutics, Inc. Stock Undervalued?
    The current Sarepta Therapeutics, Inc. [SRPT] share price is $21.53. The Score for SRPT is 50, which is 0% below its historic median score of 50, and infers higher risk than normal.
  • SRPT is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.

Will Sarepta Therapeutics, Inc. Stock Go Up Next Year?

  • Over the next 52 weeks, Sarepta Therapeutics, Inc. has on average historically risen by 28.1% based on the past 28 years of stock performance.

Sarepta Therapeutics, Inc. Stock Rating

Sell
50
Sarepta Therapeutics, Inc. (SRPT) is a Sell

Is Sarepta Therapeutics, Inc. overpriced?

  • Sarepta Therapeutics, Inc. has risen higher in 13 of those 28 years over the subsequent 52-week period, corresponding to a historical accuracy of 46.43%

Sarepta Therapeutics, Inc. Stock Price History

Is SRPT stock going to rise?

  • The current trend is moderately bullish and SRPT is experiencing slight buying pressure.

Stock Information

Stock Info

Exchange:
NASDAQ
Country:
United States
Industry:
Biotechnology
Sector:
Health Care
Type:
stock
Website:
sarepta.com

52-Week Data

52-Week High:
129.84
52-Week Low:
10.42

Prediction Charts

Market Cap:
2.3B
Price in USD:
21.53
Volume:
2M
Beta:
1.01

Technical Analysis

SMA50:
20.97
SMA100:
19.52
SMA200:
34.15
52-Wk Change:
-82.7%

Stock Predictions

  • Is Sarepta Therapeutics, Inc. stock public?
    Yes, Sarepta Therapeutics, Inc. is a publicly traded company.
  • What is the Sarepta Therapeutics, Inc. stock quote today?
    The Sarepta Therapeutics, Inc. stock price is 21.53 USD today.
  • How to buy Sarepta Therapeutics, Inc. stock online?
    You can buy Sarepta Therapeutics, Inc. shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date Opening Closing Minimum Maximum
Nov-24 17.76 18.91 19.14 17.62
Nov-25 18.91 19.35 19.45 18.73
Nov-26 19.40 20.95 21.21 19.35
Nov-28 21.11 21.34 21.38 20.72
Dec-1 20.85 19.72 21.00 19.67
Dec-2 19.82 20.47 20.53 19.37
Dec-3 19.75 21.84 21.93 19.43
Dec-4 21.55 22.82 23.00 21.47
Dec-5 22.89 22.26 22.93 21.95
Dec-8 22.53 21.86 22.67 21.44
Dec-9 22.46 22.17 22.85 21.85
Dec-10 22.11 22.20 22.67 21.84
Dec-11 21.08 21.75 21.96 20.76
Dec-12 21.72 21.53 21.74 21.18

Sarepta Therapeutics, Inc. Earnings

Sarepta Therapeutics, Inc. Earnings Report: Per Share Sarepta Therapeutics, Inc. Earnings Q1 Q2 Q3 and Q4 last year and next year.

Sarepta Therapeutics, Inc. Forecast Revenue Growth

Sarepta Therapeutics, Inc. Stock Analysis: Historical quarterly revenues per share for Sarepta Therapeutics, Inc. and historical quarterly revenue growth:

  • Analysts estimate an earnings decrease this quarter of $1.60 per share, a decrease next quarter of $0.00 per share, a decrease this year of $6.03 per share, and an increase next year of $4.91 per share.

* Sarepta Therapeutics, Inc. stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.